newsfilter
← Latest News
GlobeNewswire·

Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update

On track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome, a rare pediatric disease and